Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RKTO with free AI briefings, catalyst countdowns, and dilution alerts.

RKTO · Rocket One Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6M Cash on Hand
6.3mo Cash Runway
Follow RKTO by email Get an email when RKTO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RKTO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Xuebijing Pulmonary Disease, Chronic Obstructive Phase 4 · NCT02937974 Unknown
Mozafancogene Autotemcel Fanconi Anemia Complementation Group A Phase 2 · NCT04248439 Active not recruiting
RP-L201 Leukocyte Adhesion Defect - Type I Phase 1/2 · NCT03812263 Completed
RP-L301 Pyruvate Kinase Deficiency Phase 2 · NCT06422351 Suspended
Genetically Engineered Hematopoietic Stem… Fanconi Anemia Phase 1 · NCT01331018 Terminated
Methylprednisolone Fanconi Anemia Phase 1 · NCT01331018 Terminated
RP-A501 Danon Disease Phase 1 · NCT03882437 Completed
Autologous CD34+-enriched HSPCs Transduced with… Infantile Malignant Osteopetrosis Phase 1 · NCT04525352 Terminated

Also used in these trials (approved or third-party drugs, not RKTO's own candidates): Filgrastim, Plerixafor, Prednisone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RKTO holds $6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RKTO files for a raise →

👥 Who Owns RKTO

Insiders 2.2% Institutions (24 holders) 7% Public and other holders 90.8%
HolderTypeShares% of sharesAs of
Robb Knie
CEO and President, Director · +1.11M options
Insider 547,387 2.20% 2025-08-27

Share count 24,897,581 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RKTO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RKTO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.